|
Search
Collections
Benchmarks
Upload document
Organization
MBrace Therapeutics, Inc
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 abstract
Abstract
A multi-center, open-label phase 1/1b dose finding, safety, and pharmacokinetic study of MBRC-101, an Anth-EphA5 monomethyl auristatin (MMAE) antibody drug conjugate, in advanced refractory solid tumors.
Org:
MBrace Therapeutics, Inc,
